The following trials are currently in development or open for recruitment at Addenbrooke’s hospital in Cambridge:
|Comparison of gemcitabine-capecitabine chemotherapy combination to gemcitabine alone in patients who have undergone surgery for the removal of pancreatic cancer.||UKCRN ID 4307. Multi-centre trial. Now open to ampullary patients only.|
|Combination Gemcitabine/Nab-Paclitaxel in borderline locally advanced pancreatic cancer.||Initiated in Cambridge. UKCRN ID 16739. Open to recruitment.|
|CAM-PLEX||AMD3100 (Plerixafor)||Assessment of the safety of Plerixafor in patients with advanced pancreatic, high grade serous ovarian and colorectal adenocarcinomas.||Initiated in Cambridge. UKCRN ID 19088.
Open to recruitment.
|Assessment of ATRA in combination with gemcitabine and Nab-Paclitaxel in patients with locally advanced or metastatic pancreatic cancer.||Multi-centre trial. Open to recruitment.|
|Induction chemotherapy followed by capecitabine +/- nelfinavir, with high or standard dose radiotherapy in locally-advanced, non-metastatic pancreatic cancer.||Multi-centre trial. Open to recruitment.|
|Comparison of different schedules of the combination of Gemcitabine/Nab-Paclitaxel in patients with metastatic pancreatic cancer.||Multi-centre trial. Initiated in Cambridge. UKCRN ID 15344.
Closed to recruitment.
|Comparison of Gemcitabine/Nab-Paclitaxel combination to Gemcitabine alone as adjuvant therapy for patients who have undergone surgery for the removal of pancreatic cancer.||Multi-centre international trial. Closed to recruitment.|
- These trials cover different stages of disease, and will therefore be relevant for different groups of patients. The trials that were conceived and designed in Cambridge have been indicated.
- We are constantly following new leads on potential therapies, and have a number of other trials that are currently under development. This page will be updated when these studies open.